Compare DraftKings Inc (DKNG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs IDEXX Laboratories, Inc. — how do they compare? DraftKings Inc trades at $25.71 (market cap $12.58B), while IDEXX Laboratories, Inc. trades at $572.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.7× DraftKings Inc's market cap. Which is the better fit depends on your goals.
| DKNG | IDXX | |
|---|---|---|
Market Cap | $12.58B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $766.68 |
52-Week Low | $20.72 | $526.44 |
Enterprise Value | $13.51B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $25.65, up 5.69% on the day, with a bullish technical signal and strong analyst support. The company reported mixed Q2 2026 results, missing earnings estimates but showing robust prediction market growth. Revenue reached $6.05B in 2025, with positive net income of $3.71M, marking a significant turnaround from prior losses. Cash flow from operations improved to $662.86M, though net cash flow turned negative in 2026 projections.
The outlook is cautiously optimistic, driven by prediction market expansion and cost management, but risks include intense competition and promotional pressures. With a consensus price target of $34.00 and 73% buy ratings, upside potential exists if execution continues. Investors should weigh growth prospects against valuation premiums and earnings volatility.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
